Inhibition of p38 signaling curtails the SARS-CoV-2 induced inflammatory response but retains the IFN-dependent antiviral defense of the lung epithelial barrier

SARS-CoV-2 is the causative agent of the immune response-driven disease COVID-19 for which new antiviral and anti-inflammatory treatments are urgently needed to reduce recovery time, risk of death and long COVID development. Here, we demonstrate that the immunoregulatory kinase p38 MAPK is activated...

Descripción completa

Detalles Bibliográficos
Autores principales: Faist, Aileen, Schloer, Sebastian, Mecate-Zambrano, Angeles, Janowski, Josua, Schreiber, André, Boergeling, Yvonne, Conrad, Beate C.G., Kumar, Sriram, Toebben, Leonie, Schughart, Klaus, Baumgardt, Morris, Kessler, Mirjana, Hoenzke, Katja, Hocke, Andreas, Trautmann, Marcel, Hartmann, Wolfgang, Kato, Hiroki, Rescher, Ursula, Christersson, Anmari, Kuehn, Joachim, Mellmann, Alexander, Wolff, Thorsten, Kuempers, Philip, Rovas, Alexandros, Wiewrodt, Rainer, Wiebe, Karsten, Barth, Peter, Ludwig, Stephan, Brunotte, Linda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier B.V. 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9677559/
https://www.ncbi.nlm.nih.gov/pubmed/36423831
http://dx.doi.org/10.1016/j.antiviral.2022.105475

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9677559/
https://www.ncbi.nlm.nih.gov/pubmed/36423831
http://dx.doi.org/10.1016/j.antiviral.2022.105475

Ejemplares similares